MREO

Mereo BioPharma
MREO
Market cap $404M

2.54 USD

+0.02

0.79%

Updated Apr 30, 1:16 PM EDT

1 day

0.79%

5 days

-0.39%

1 month

12.89%

3 months

-13.31%

6 months

-40.24%

Year to date

-25.73%

1 year

-16.72%

5 years

85.40%

10 years

-60.92%

About: Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Employees: 36

Healthcare Biotechnology

0

Funds holding %

of 7,425 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

186% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 7

65% more call options, than puts

Call options by funds: $3.02M | Put options by funds: $1.84M

17% more funds holding

Funds holding: 77 [Q3] → 90 (+13) [Q4]

1.1% more ownership

Funds ownership: 13.75% [Q3] → 14.85% (+1.1%) [Q4]

7% less capital invested

Capital invested by funds: $435M [Q3] → $403M (-$31.6M) [Q4]

20% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 25

33% less funds holding in top 10

Funds holding in top 10: 3 [Q3] → 2 (-1) [Q4]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$7

176%

upside

Avg. target

$7

176%

upside

High target

$7

176%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

Needham Gil Blum 18% 1-year accuracy 29 / 158 met price target	176%upside $7	Buy Reiterated	9 Apr 2025
JP Morgan Priyanka Grover 0% 1-year accuracy 0 / 1 met price target	176%upside $7	Overweight Initiated	27 Mar 2025
Cantor Fitzgerald Kristen Kluska 24% 1-year accuracy 24 / 101 met price target	176%upside $7	Overweight Reiterated	18 Mar 2025

See Analyst Rankings

Financial journalist opinion

Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights

Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025

Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights

Zacks Investment Research

MEREO BIOPHARMA (MREO) Upgraded to Buy: What Does It Mean for the Stock?

MEREO BIOPHARMA (MREO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

MEREO BIOPHARMA (MREO) Upgraded to Buy: What Does It Mean for the Stock?

Hidden Gems: 5 Stocks Under $10 With Massive Growth Potential

Stocks priced under $10 present an attractive entry point into the market for investors seeking to maximize portfolio diversification and growth potential without a significant upfront capital outlay. These affordable equities allow investors to acquire a larger number of shares for a given investment and can yield substantial percentage gains.

Hidden Gems: 5 Stocks Under $10 With Massive Growth Potential

Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference

LONDON, March 05, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Wednesday, March 12, 2025, at 8:40 am ET / 1:40 pm GMT.

Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference

Mereo BioPharma Provides Update on Lead Clinical Programs

Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025

Mereo BioPharma Provides Update on Lead Clinical Programs

Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

LONDON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025, at 8:15am PT / 04:15pm GMT.

Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Mereo BioPharma: Setrusumab Chugs Along With Possible Inflection Points

Mereo BioPharma Group plc's setrusumab shows promise in treating osteogenesis imperfecta, with phase 3 studies fully enrolled and potential for multiple catalysts in 2025. Positive 14-month data from the phase 2/3 ORBIT study indicates a significant reduction in fracture rates, bolstering confidence in ongoing phase 3 trials. Financially stable with $87.4 million in cash, Mereo aims to secure a partner for Alvelestat's phase 3 trial, potentially boosting stock value.

Mereo BioPharma: Setrusumab Chugs Along With Possible Inflection Points

Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference

LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 10:30am ET / 03:30pm GMT.

Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Setrusumab receives Breakthrough Therapy designation from the FDA Cash of $80.5 million as of September 30, 2024, expected to fund operations into 2027 LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the third quarter ended September 30, 2024, and provided an update on recent corporate highlights. The Company reported cash and cash equivalents of $80.5 million as of September 30, 2024, which the Company believes will provide runway into 2027, through multiple key inflection points.

Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference

LONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 10:55am ET / 03:55pm BST.

Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference

See News Rankings

Charts implemented using Lightweight Charts™